Compare AbbVie Inc (ABBV) vs Newegg Commerce Inc (NEGG) Price & Performance

AbbVie (ABBV) trades at $252.92, down 0.72% on the day, with strong technical support at $251 and resistance at $258. The stock shows bullish momentum with recent earnings beats and a consensus analyst price target of $266.33. Revenue grew to $61.16B in 2025, though net margins compressed to 5.79%. Key growth drivers include Skyrizi and Rinvoq offsetting Humira declines, supported by positive Phase 2 data for ELAHERE in ovarian cancer (PRNewsWire, 2026-04-12).

Outlook remains positive with immunology portfolio strength and dividend growth, but risks include patent cliffs in the 2030s and high debt levels. Institutional buying and 68% analyst buy ratings suggest confidence, though valuation multiples like P/E of 124.83 warrant caution. Near-term catalysts include Q2 2026 earnings expected at $3.79 EPS.

NEGG trades at $14.94 with minimal daily movement (+0.2%). The stock shows mixed signals with a bearish technical outlook but positive analyst sentiment. Recent financials reveal modest revenue growth to $1.44B in 2025, though profitability remains challenged with a net loss of $4.88M. The company is investing in AI shopping experiences and promotional events to drive growth.

While analyst consensus is bullish (100% buy rating), fundamental weaknesses including negative cash flow from operations and thin margins present risks. The stock's valuation appears stretched with a P/E of 57.14, suggesting limited near-term upside without significant earnings improvement.